|
BE792533A
(fr)
|
1971-12-09 |
1973-06-08 |
Int Chem & Nuclear Corp |
Nouvelles pyrazolo (1,5a) pyrimidines et leur procede de preparation
|
|
AU600575B2
(en)
|
1987-03-18 |
1990-08-16 |
Sb2, Inc. |
Altered antibodies
|
|
US5859205A
(en)
|
1989-12-21 |
1999-01-12 |
Celltech Limited |
Humanised antibodies
|
|
US5994514A
(en)
|
1991-08-14 |
1999-11-30 |
Genentech, Inc. |
Immunoglobulin variants
|
|
CA2118508A1
(en)
|
1992-04-24 |
1993-11-11 |
Elizabeth S. Ward |
Recombinant production of immunoglobulin-like domains in prokaryotic cells
|
|
WO1994029351A2
(en)
|
1993-06-16 |
1994-12-22 |
Celltech Limited |
Antibodies
|
|
CA2143491C
(en)
|
1994-03-01 |
2011-02-22 |
Yasumasa Ishida |
A novel peptide related to human programmed cell death and dna encoding it
|
|
JP2778921B2
(ja)
|
1994-11-18 |
1998-07-23 |
三共株式会社 |
イミダゾピラゾール誘導体
|
|
US6528624B1
(en)
|
1998-04-02 |
2003-03-04 |
Genentech, Inc. |
Polypeptide variants
|
|
US6194551B1
(en)
|
1998-04-02 |
2001-02-27 |
Genentech, Inc. |
Polypeptide variants
|
|
GB9809951D0
(en)
|
1998-05-08 |
1998-07-08 |
Univ Cambridge Tech |
Binding molecules
|
|
US6737056B1
(en)
|
1999-01-15 |
2004-05-18 |
Genentech, Inc. |
Polypeptide variants with altered effector function
|
|
BR0008758A
(pt)
|
1999-01-15 |
2001-12-04 |
Genentech Inc |
Variantes de polipeptìdeos parentais com funçãoefetora alterada, polipeptìdeos, composição ácidonucleico isolado, vetor, célula hospedeira,método para produzir uma variante depolipeptìdeo, método para o tratamento de umadesordem em mamìferos e método para produziruma região fc variante
|
|
EP1210428B1
(en)
|
1999-08-23 |
2015-03-18 |
Dana-Farber Cancer Institute, Inc. |
Pd-1, a receptor for b7-4, and uses therefor
|
|
JP5004390B2
(ja)
|
1999-08-23 |
2012-08-22 |
デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド |
新規ｂ７−４分子およびその用途
|
|
ES2222919T3
(es)
|
1999-08-27 |
2005-02-16 |
Abbott Laboratories |
Compuestos sulfonilfenilpirazoles utiles como inhibidores de cox-2.
|
|
PT1212327E
(pt)
|
1999-09-17 |
2004-01-30 |
Abbott Gmbh & Co Kg |
Pirazolopirimidinas como agentes terapeuticos
|
|
EP1266014A2
(en)
|
2000-03-24 |
2002-12-18 |
Peter Kufer |
Multifunctional polypeptides comprising a binding site to an epitope of the nkg2d receptor complex
|
|
AU5345901A
(en)
|
2000-04-13 |
2001-10-30 |
Univ Rockefeller |
Enhancement of antibody-mediated immune responses
|
|
WO2002020740A2
(en)
|
2000-09-08 |
2002-03-14 |
California Institute Of Technology |
Proteolysis targeting chimeric pharmaceutical
|
|
US20020094989A1
(en)
|
2000-10-11 |
2002-07-18 |
Hale Jeffrey J. |
Pyrrolidine modulators of CCR5 chemokine receptor activity
|
|
KR20030066657A
(ko)
|
2000-11-15 |
2003-08-09 |
오노 야꾸힝 고교 가부시키가이샤 |
Ｐｄ-1 결손 마우스 및 그 용도
|
|
PT1355919E
(pt)
|
2000-12-12 |
2011-03-02 |
Medimmune Llc |
Moléculas com semivida longa, composições que as contêm e suas utilizações
|
|
HUP0303538A2
(hu)
|
2000-12-21 |
2005-02-28 |
Bristol-Myers Squibb Co. |
Tirozin kinázok Tec családjának tiazolil-vegyület inhibitorai és ezeket tartalmazó gyógyszerkészítmények
|
|
US20030133939A1
(en)
|
2001-01-17 |
2003-07-17 |
Genecraft, Inc. |
Binding domain-immunoglobulin fusion proteins
|
|
BR0207854A
(pt)
|
2001-03-07 |
2004-08-24 |
Merck Patent Gmbh |
Tecnologia de expressão para proteìnas contendo uma porção de anticorpo de isotipo hìbrido
|
|
CA2440211A1
(en)
|
2001-03-09 |
2002-09-19 |
Pfizer Products Inc. |
Benzimidazole anti-inflammatory compounds
|
|
AR036993A1
(es)
|
2001-04-02 |
2004-10-20 |
Wyeth Corp |
Uso de agentes que modulan la interaccion entre pd-1 y sus ligandos en la submodulacion de respuestas inmunologicas
|
|
WO2003004497A1
(en)
|
2001-07-05 |
2003-01-16 |
Sumitomo Pharmaceuticals Company, Limited |
Novel heterocyclic compound
|
|
US7317091B2
(en)
|
2002-03-01 |
2008-01-08 |
Xencor, Inc. |
Optimized Fc variants
|
|
US7662925B2
(en)
|
2002-03-01 |
2010-02-16 |
Xencor, Inc. |
Optimized Fc variants and methods for their generation
|
|
AU2003281200A1
(en)
|
2002-07-03 |
2004-01-23 |
Tasuku Honjo |
Immunopotentiating compositions
|
|
CA2494700C
(en)
|
2002-08-26 |
2011-06-28 |
Takeda Pharmaceutical Company Limited |
Calcium receptor modulating compound and use thereof
|
|
CN1771231B
(zh)
|
2002-08-26 |
2011-05-25 |
武田药品工业株式会社 |
钙受体调节性化合物及其用途
|
|
NZ538996A
(en)
|
2002-10-31 |
2008-04-30 |
Genentech Inc |
Methods and compositions for increasing antibody production
|
|
CN101899114A
(zh)
|
2002-12-23 |
2010-12-01 |
惠氏公司 |
抗pd-1抗体及其用途
|
|
US7960512B2
(en)
|
2003-01-09 |
2011-06-14 |
Macrogenics, Inc. |
Identification and engineering of antibodies with variant Fc regions and methods of using same
|
|
EP1587540B1
(en)
|
2003-01-09 |
2021-09-15 |
MacroGenics, Inc. |
IDENTIFICATION AND ENGINEERING OF ANTIBODIES WITH VARIANT Fc REGIONS AND METHODS OF USING SAME
|
|
EP1591527B1
(en)
|
2003-01-23 |
2015-08-26 |
Ono Pharmaceutical Co., Ltd. |
Substance specific to human pd-1
|
|
US8084582B2
(en)
|
2003-03-03 |
2011-12-27 |
Xencor, Inc. |
Optimized anti-CD20 monoclonal antibodies having Fc variants
|
|
WO2005014599A1
(en)
|
2003-06-04 |
2005-02-17 |
Cellular Genomics, Inc. |
Imidazo[1,2-a]pyrazin-8-ylamines and method of inhibition of bruton’s tyrosine kinase by such compounds
|
|
US20060183746A1
(en)
|
2003-06-04 |
2006-08-17 |
Currie Kevin S |
Certain imidazo[1,2-a]pyrazin-8-ylamines and method of inhibition of Bruton's tyrosine kinase by such compounds
|
|
US7393848B2
(en)
|
2003-06-30 |
2008-07-01 |
Cgi Pharmaceuticals, Inc. |
Certain heterocyclic substituted imidazo[1,2-A]pyrazin-8-ylamines and methods of inhibition of Bruton's tyrosine kinase by such compounds
|
|
CN1860118A
(zh)
|
2003-07-29 |
2006-11-08 |
Irm责任有限公司 |
作为蛋白激酶抑制剂的化合物和组合物
|
|
NZ545776A
(en)
|
2003-08-22 |
2009-05-31 |
Biogen Idec Inc |
Improved antibodies having altered effector function and methods for making the same
|
|
US20060134105A1
(en)
|
2004-10-21 |
2006-06-22 |
Xencor, Inc. |
IgG immunoglobulin variants with optimized effector function
|
|
US20050288295A1
(en)
|
2003-11-11 |
2005-12-29 |
Currie Kevin S |
Certain imidazo[1,2-a]pyrazin-8-ylamines, method of making, and method of use thereof
|
|
WO2005077981A2
(en)
|
2003-12-22 |
2005-08-25 |
Xencor, Inc. |
Fc POLYPEPTIDES WITH NOVEL Fc LIGAND BINDING SITES
|
|
GB0400440D0
(en)
|
2004-01-09 |
2004-02-11 |
Isis Innovation |
Receptor modulators
|
|
WO2006029459A1
(en)
*
|
2004-09-13 |
2006-03-23 |
Evogenix, Inc |
Antibodies specific for hepatocellular carcinoma and other carcinomas and uses thereof
|
|
EP1810979B1
(en)
|
2004-09-22 |
2012-06-20 |
Kyowa Hakko Kirin Co., Ltd. |
STABILIZED HUMAN IgG4 ANTIBODIES
|
|
WO2006053121A2
(en)
|
2004-11-10 |
2006-05-18 |
Cgi Pharmaceuticals, Inc. |
Imidazo[1 , 2-a] pyrazin-8-ylamines useful as modulators of kinase activity
|
|
US8101770B2
(en)
|
2004-12-16 |
2012-01-24 |
Vertex Pharmaceuticals Incorporated |
Pyridones useful as inhibitors of kinases
|
|
TW200639163A
(en)
|
2005-02-04 |
2006-11-16 |
Genentech Inc |
RAF inhibitor compounds and methods
|
|
CA2601628C
(en)
|
2005-03-10 |
2014-05-13 |
Cgi Pharmaceuticals, Inc. |
Certain substituted amides, method of making, and method of use thereof
|
|
CN109485727A
(zh)
|
2005-05-09 |
2019-03-19 |
小野药品工业株式会社 |
程序性死亡-1(pd-1)的人单克隆抗体及使用抗pd-1抗体来治疗癌症的方法
|
|
EP3130350A1
(en)
|
2005-06-08 |
2017-02-15 |
Dana-Farber Cancer Institute, Inc. |
Methods and compositions for the treatment of persistent infections and cancer by inhibiting the programmed cell death 1 (pd-1)pathway
|
|
KR101411165B1
(ko)
|
2005-07-01 |
2014-06-25 |
메다렉스, 엘.엘.시. |
예정 사멸 리간드 1 (피디-엘1)에 대한 인간 모노클로날항체
|
|
WO2007027594A1
(en)
|
2005-08-29 |
2007-03-08 |
Vertex Pharmaceuticals Incorporated |
3,5-disubstituted pyrid-2-ones useful as inhibitors of tec family of non-receptor tyrosine kinases
|
|
ATE528302T1
(de)
|
2005-08-29 |
2011-10-15 |
Vertex Pharma |
3,5-disubstituierte pyrid-2-one, die als hemmer der tec-familie von nicht-rezeptor tyrosin- kinasen nützlich sind
|
|
WO2007026720A1
(ja)
|
2005-08-31 |
2007-03-08 |
Taisho Pharmaceutical Co., Ltd. |
縮環ピラゾール誘導体
|
|
WO2007026950A1
(en)
|
2005-09-01 |
2007-03-08 |
Astellas Pharma Inc. |
Pyridazinone derivatives used for the treatment of pain
|
|
KR20080074220A
(ko)
|
2005-12-08 |
2008-08-12 |
밀레니엄 파머슈티컬스 인코퍼레이티드 |
키나아제 억제 활성을 갖는 비시클릭 화합물
|
|
AU2006336506B2
(en)
|
2006-01-13 |
2012-06-28 |
Pharmacyclics Llc |
Inhibitors of tyrosine kinases and uses thereof
|
|
BRPI0709050B1
(pt)
|
2006-03-23 |
2018-12-26 |
Bioarctic Neuroscience Ab |
anticorpo ou fragmento do mesmo, composição, métodos para detectar protofibrilas ab in vitro, e, uso do anticorpo
|
|
ATE552245T1
(de)
|
2006-05-15 |
2012-04-15 |
Merck Sharp & Dohme |
Antidiabetische bicyclische verbindungen
|
|
CA2651732C
(en)
|
2006-05-18 |
2014-10-14 |
Mannkind Corporation |
Intracellular kinase inhibitors
|
|
JO3235B1
(ar)
|
2006-05-26 |
2018-03-08 |
Astex Therapeutics Ltd |
مركبات بيررولوبيريميدين و استعمالاتها
|
|
CN101104640A
(zh)
|
2006-07-10 |
2008-01-16 |
苏州大学 |
抗人pd-l1单克隆抗体制备及应用
|
|
EP2068849A2
(en)
|
2006-09-11 |
2009-06-17 |
CGI Pharmaceuticals, Inc. |
Kinase inhibitors, and methods of using and identifying kinase inhibitors
|
|
AR063946A1
(es)
|
2006-09-11 |
2009-03-04 |
Cgi Pharmaceuticals Inc |
Determinadas pirimidinas sustituidas, el uso de las mismas para el tratamiento de enfermedades mediadas por la inhibicion de la actividad de btk y composiciones farmaceuticas que las comprenden.
|
|
AR063707A1
(es)
|
2006-09-11 |
2009-02-11 |
Cgi Pharmaceuticals Inc |
Determinadas amidas sustituidas, el uso de las mismas para el tratamiento de enfermedades mediadas por la inhibicion de la actividad de btk y composiciones farmacéuticas que las comprenden.
|
|
AR063706A1
(es)
|
2006-09-11 |
2009-02-11 |
Cgi Pharmaceuticals Inc |
Determinadas amidas sustituidas, el uso de las mismas para el tratamiento de enfermedades mediadas por la inhibicion de la actividad de btk y composiciones farmaceuticas que las comprenden.
|
|
EP2526934B1
(en)
|
2006-09-22 |
2015-12-09 |
Pharmacyclics LLC |
Inhibitors of bruton's tyrosine kinase
|
|
CN101522026A
(zh)
|
2006-10-06 |
2009-09-02 |
Irm责任有限公司 |
蛋白激酶抑制剂及其应用方法
|
|
EP2089391B1
(en)
|
2006-11-03 |
2013-01-16 |
Pharmacyclics, Inc. |
Bruton's tyrosine kinase activity probe and method of using
|
|
WO2008116064A2
(en)
|
2007-03-21 |
2008-09-25 |
Bristol-Myers Squibb Company |
Fused heterocyclic compounds useful for the treatment of proliferative, allergic, autoimmune or inflammatory diseases
|
|
WO2008144253A1
(en)
|
2007-05-14 |
2008-11-27 |
Irm Llc |
Protein kinase inhibitors and methods for using thereof
|
|
WO2008145142A1
(en)
|
2007-05-31 |
2008-12-04 |
Genmab A/S |
Stable igg4 antibodies
|
|
NZ600758A
(en)
|
2007-06-18 |
2013-09-27 |
Merck Sharp & Dohme |
Antibodies to human programmed death receptor pd-1
|
|
EP2195347A1
(en)
|
2007-08-17 |
2010-06-16 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Method for treating and diagnosing hematologic malignancies
|
|
CL2008002793A1
(es)
|
2007-09-20 |
2009-09-04 |
Cgi Pharmaceuticals Inc |
Compuestos derivados de amidas sustituidas, inhibidores de la actividad de btk; composicion farmaceutica que los comprende; utiles en el tratamiento del cancer, trastornos oseos, enfermedades autoinmunes, entre otras
|
|
JO3076B1
(ar)
|
2007-10-17 |
2017-03-15 |
Janssen Alzheimer Immunotherap |
نظم العلاج المناعي المعتمد على حالة apoe
|
|
US7989465B2
(en)
|
2007-10-19 |
2011-08-02 |
Avila Therapeutics, Inc. |
4,6-disubstituted pyrimidines useful as kinase inhibitors
|
|
JP5600063B2
(ja)
|
2007-10-19 |
2014-10-01 |
セルジーン アビロミクス リサーチ， インコーポレイテッド |
ヘテロアリール化合物およびその使用
|
|
CA2701275C
(en)
|
2007-10-23 |
2016-06-21 |
F. Hoffmann-La Roche Ag |
Kinase inhibitors
|
|
CN101952283B
(zh)
|
2007-12-14 |
2013-04-17 |
霍夫曼-拉罗奇有限公司 |
咪唑并[1，2-a]吡啶和咪唑并[1，2-b]哒嗪衍生物
|
|
WO2009098144A1
(en)
|
2008-02-05 |
2009-08-13 |
F. Hoffmann-La Roche Ag |
Novel pyridinones and pyridazinones
|
|
HUE028958T2
(en)
|
2008-02-08 |
2017-01-30 |
Medimmune Llc |
Anti-ifnar1 antibodies with reduced fc ligand affinity
|
|
EP2262837A4
(en)
|
2008-03-12 |
2011-04-06 |
Merck Sharp & Dohme |
PD-1 BINDING PROTEINS
|
|
WO2009137596A1
(en)
|
2008-05-06 |
2009-11-12 |
Cgi Pharmaceuticals, Inc. |
Substituted amides, method of making, and use as btk inhibitors
|
|
EP2361248B1
(en)
|
2008-06-27 |
2018-09-19 |
Celgene CAR LLC |
Heteroaryl compounds and uses thereof
|
|
US8338439B2
(en)
|
2008-06-27 |
2012-12-25 |
Celgene Avilomics Research, Inc. |
2,4-disubstituted pyrimidines useful as kinase inhibitors
|
|
PL2300459T3
(pl)
|
2008-07-02 |
2013-10-31 |
Hoffmann La Roche |
Nowe fenylopirazynony jako inhibitory kinazy
|
|
EP2307413B1
(en)
|
2008-07-15 |
2015-09-09 |
F. Hoffmann-La Roche AG |
Novel phenyl-imidazopyridines and pyridazines
|
|
MX2011000661A
(es)
|
2008-07-16 |
2011-05-25 |
Pharmacyclics Inc |
Inhibidores de tirosina cinasa de bruton para el tratamiento de tumores solidos.
|
|
CA2725512C
(en)
|
2008-07-18 |
2016-06-28 |
F. Hoffmann-La Roche Ag |
Novel phenylimidazopyrazines
|
|
EP2323665B1
(en)
|
2008-07-24 |
2013-06-19 |
Bristol-Myers Squibb Company |
Fused heterocyclic compounds useful as kinase modulators
|
|
CA2735006A1
(en)
|
2008-08-25 |
2010-03-11 |
Amplimmune, Inc. |
Pd-1 antagonists and methods of use thereof
|
|
CN105574346A
(zh)
|
2008-09-05 |
2016-05-11 |
新基阿维罗米克斯研究公司 |
多肽偶联物与不可逆抑制剂的设计方法和检测方法
|
|
EP2342228B1
(en)
|
2008-09-12 |
2017-09-06 |
Oxford University Innovation Limited |
Pd-1 specific antibodies and uses thereof
|
|
EP2342229A1
(en)
|
2008-09-12 |
2011-07-13 |
ISIS Innovation Limited |
Pd-1 specific antibodies and uses thereof
|
|
ES2592216T3
(es)
|
2008-09-26 |
2016-11-28 |
Dana-Farber Cancer Institute, Inc. |
Anticuerpos anti-PD-1, PD-L1 y PD-L2 humanos y sus usos
|
|
KR101050829B1
(ko)
|
2008-10-02 |
2011-07-20 |
서울대학교산학협력단 |
항 ｐｄ-1 항체 또는 항 ｐｄ-ｌ1 항체를 포함하는 항암제
|
|
CA2740792C
(en)
|
2008-10-31 |
2016-06-21 |
Genentech, Inc. |
Pyrazolopyrimidine jak inhibitor compounds and methods
|
|
US20120028981A1
(en)
|
2008-11-05 |
2012-02-02 |
Principia Biopharma Inc. |
Kinase Knockdown Via Electrophilically Enhanced Inhibitors
|
|
WO2010056875A1
(en)
|
2008-11-12 |
2010-05-20 |
Cgi Pharmaceuticals, Inc. |
Pyridazinones and their use as btk inhibitors
|
|
CN102282265B
(zh)
|
2008-11-28 |
2020-07-24 |
埃默里大学 |
用于治疗传染病和肿瘤的方法
|
|
US8426428B2
(en)
|
2008-12-05 |
2013-04-23 |
Principia Biopharma, Inc. |
EGFR kinase knockdown via electrophilically enhanced inhibitors
|
|
WO2010077634A1
(en)
|
2008-12-09 |
2010-07-08 |
Genentech, Inc. |
Anti-pd-l1 antibodies and their use to enhance t-cell function
|
|
WO2010068810A2
(en)
|
2008-12-10 |
2010-06-17 |
Cgi Pharmaceuticals, Inc. |
Certain substituted amides, method of making, and method of use thereof
|
|
WO2010068806A1
(en)
|
2008-12-10 |
2010-06-17 |
Cgi Pharmaceuticals, Inc. |
Amide derivatives as btk inhibitors in the treatment of allergic, autoimmune and inflammatory disorders as well as cancer
|
|
WO2010068788A1
(en)
|
2008-12-10 |
2010-06-17 |
Cgi Pharmaceuticals, Inc. |
Heterocyclic amides as btk inhibitors
|
|
CN102325753B
(zh)
|
2008-12-19 |
2014-09-10 |
百时美施贵宝公司 |
用作激酶抑制剂的咔唑甲酰胺化合物
|
|
US20100197924A1
(en)
|
2008-12-22 |
2010-08-05 |
Millennium Pharmaceuticals, Inc. |
Preparation of aminotetralin compounds
|
|
EP2379559B1
(en)
|
2009-01-06 |
2017-10-25 |
Dana-Farber Cancer Institute, Inc. |
Pyrimido-diazepinone kinase scaffold compounds and methods of treating disorders
|
|
US8741295B2
(en)
|
2009-02-09 |
2014-06-03 |
Universite De La Mediterranee |
PD-1 antibodies and PD-L1 antibodies and uses thereof
|
|
US8299077B2
(en)
|
2009-03-02 |
2012-10-30 |
Roche Palo Alto Llc |
Inhibitors of Bruton's tyrosine kinase
|
|
SG175287A1
(en)
|
2009-04-24 |
2011-11-28 |
Hoffmann La Roche |
Inhibitors of bruton's tyrosine kinase
|
|
EP2424368B1
(en)
|
2009-04-29 |
2014-12-31 |
Locus Pharmaceuticals, Inc. |
Pyrrolotriazine compounds
|
|
JP2012529535A
(ja)
|
2009-06-12 |
2012-11-22 |
ブリストル−マイヤーズ スクイブ カンパニー |
キナーゼモジュレーターとして有用なニコチンアミド化合物
|
|
AR077468A1
(es)
|
2009-07-09 |
2011-08-31 |
Array Biopharma Inc |
Compuestos de pirazolo (1,5 -a) pirimidina sustituidos como inhibidores de trk- quinasa
|
|
EP2464647B1
(en)
|
2009-08-11 |
2016-09-21 |
Bristol-Myers Squibb Company |
Azaindazoles as btk kinase modulators and use thereof
|
|
US9493578B2
(en)
|
2009-09-02 |
2016-11-15 |
Xencor, Inc. |
Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens
|
|
TWI711610B
(zh)
|
2009-09-04 |
2020-12-01 |
美商百健Ｍａ公司 |
布魯頓氏酪胺酸激酶抑制劑
|
|
EP2485589A4
(en)
|
2009-09-04 |
2013-02-06 |
Biogen Idec Inc |
HETEROARYL-BTK INHIBITORS
|
|
US7741330B1
(en)
|
2009-10-12 |
2010-06-22 |
Pharmacyclics, Inc. |
Pyrazolo-pyrimidine inhibitors of Bruton's tyrosine kinase
|
|
US8389689B2
(en)
|
2009-10-28 |
2013-03-05 |
Janssen Biotech, Inc. |
Anti-GLP-1R antibodies and their uses
|
|
US10053513B2
(en)
|
2009-11-30 |
2018-08-21 |
Janssen Biotech, Inc. |
Antibody Fc mutants with ablated effector functions
|
|
PL2536745T3
(pl)
|
2010-02-19 |
2017-01-31 |
Xencor, Inc. |
Nowe immunoadhezyny CTLA4-IG
|
|
RU2012145183A
(ru)
|
2010-03-29 |
2014-05-10 |
Займворкс, Инк. |
Антитела с повышенной или пониженной эффекторной функцией
|
|
EP2566869B1
(en)
|
2010-05-07 |
2016-03-02 |
Gilead Connecticut, Inc. |
Pyridone and aza-pyridone compounds and methods of use
|
|
AU2011260961B9
(en)
|
2010-05-31 |
2015-02-26 |
Ono Pharmaceutical Co., Ltd. |
Purinone derivative
|
|
NZ604040A
(en)
|
2010-06-03 |
2015-02-27 |
Pharmacyclics Inc |
The use of inhibitors of bruton’s tyrosine kinase (btk)
|
|
WO2011159857A1
(en)
|
2010-06-16 |
2011-12-22 |
Bristol-Myers Squibb Company |
Carboline carboxamide compounds useful as kinase inhibitors
|
|
CA2803056C
(en)
|
2010-06-23 |
2017-05-16 |
Hanmi Science Co., Ltd. |
Fused pyrimidine derivatives for inhibition of tyrosine kinase activity
|
|
US20120053189A1
(en)
|
2010-06-28 |
2012-03-01 |
Pharmacyclics, Inc. |
Btk inhibitors for the treatment of immune mediated conditions
|
|
WO2012009705A1
(en)
|
2010-07-15 |
2012-01-19 |
Zyngenia, Inc. |
Ang-2 binding complexes and uses thereof
|
|
NZ607845A
(en)
|
2010-08-10 |
2015-03-27 |
Celgene Avilomics Res Inc |
Besylate salt of a btk inhibitor
|
|
AR082590A1
(es)
|
2010-08-12 |
2012-12-19 |
Hoffmann La Roche |
Inhibidores de la tirosina-quinasa de bruton
|
|
CN106220614B
(zh)
|
2010-09-01 |
2019-07-16 |
吉利德康涅狄格有限公司 |
吡啶酮/吡嗪酮、其制备方法及使用方法
|
|
KR101864908B1
(ko)
|
2010-09-01 |
2018-06-05 |
질레드 코네티컷 인코포레이티드 |
피리다지논, 그의 제조 방법 및 사용 방법
|
|
CN103429261A
(zh)
|
2010-12-22 |
2013-12-04 |
塞法隆澳大利亚股份有限公司 |
半寿期改进的修饰抗体
|
|
KR20160044598A
(ko)
|
2011-03-29 |
2016-04-25 |
로슈 글리카트 아게 |
항체 Fc 변이체
|
|
US9220776B2
(en)
|
2011-03-31 |
2015-12-29 |
Merck Sharp & Dohme Corp. |
Stable formulations of antibodies to human programmed death receptor PD-1 and related treatments
|
|
CN103889962B
(zh)
|
2011-04-01 |
2017-05-03 |
犹他大学研究基金会 |
作为受体酪氨酸激酶btk抑制剂的取代的n‑(3‑(嘧啶‑4‑基)苯基)丙烯酰胺类似物
|
|
CA2760174A1
(en)
|
2011-12-01 |
2013-06-01 |
Pharmascience Inc. |
Protein kinase inhibitors and uses thereof
|
|
WO2012143522A1
(en)
|
2011-04-20 |
2012-10-26 |
Glaxo Group Limited |
Tetrahydropyrazolo [1,5 -a] pyrimidine as anti -tuberculosis compounds
|
|
PL2699264T3
(pl)
|
2011-04-20 |
2018-08-31 |
Medimmune, Llc |
Przeciwciała i inne cząsteczki wiążące B7-H1 i PD-1
|
|
SI2710005T1
(sl)
|
2011-05-17 |
2017-03-31 |
Principia Biopharma Inc. |
Zaviralci tirozinske kinaze
|
|
AU2012257802A1
(en)
|
2011-05-17 |
2013-10-31 |
F. Hoffmann-La Roche Ag |
Inhibitors of Bruton's tyrosine kinase
|
|
US20140107151A1
(en)
|
2011-05-17 |
2014-04-17 |
Principia Biophama Inc. |
Tyrosine kinase inhibitors
|
|
US9376438B2
(en)
|
2011-05-17 |
2016-06-28 |
Principia Biopharma, Inc. |
Pyrazolopyrimidine derivatives as tyrosine kinase inhibitors
|
|
RU2616881C2
(ru)
|
2011-06-06 |
2017-04-18 |
Ново Нордиск А/С |
Терапевтические антитела
|
|
KR20180084153A
(ko)
|
2011-06-10 |
2018-07-24 |
메르크 파텐트 게엠베하 |
Btk 억제 활성을 갖는 피리미딘 및 피리딘 화합물의 조성물 및 제조방법
|
|
AU2012273955A1
(en)
|
2011-06-22 |
2014-01-09 |
Inserm (Institut National De La Sante Et De La Recherche Medicale) |
Anti-Axl antibodies and uses thereof
|
|
CN103732596B
(zh)
|
2011-07-08 |
2016-06-01 |
诺华股份有限公司 |
吡咯并嘧啶衍生物
|
|
AR087405A1
(es)
|
2011-08-01 |
2014-03-19 |
Genentech Inc |
Metodos para tratar el cancer por el uso de antagonistas de union al eje pd-1 e inhibidores de mek
|
|
EP2785375B1
(en)
|
2011-11-28 |
2020-07-22 |
Merck Patent GmbH |
Anti-pd-l1 antibodies and uses thereof
|
|
KR102438072B1
(ko)
|
2012-01-12 |
2022-08-31 |
예일 유니버시티 |
E3 유비퀴틴 리가아제에 의한 표적 단백질 및 다른 폴리펩티드의 증진된 분해를 위한 화합물 및 방법
|
|
SG11201404751UA
(en)
|
2012-02-09 |
2014-09-26 |
Chugai Pharmaceutical Co Ltd |
Modified fc region of antibody
|
|
ES2746103T3
(es)
|
2012-04-30 |
2020-03-04 |
Medimmune Llc |
Moléculas con función efectora reducida y semividas prolongadas, composiciones y usos de las mismas
|
|
US9856320B2
(en)
|
2012-05-15 |
2018-01-02 |
Bristol-Myers Squibb Company |
Cancer immunotherapy by disrupting PD-1/PD-L1 signaling
|
|
CN104736168B
(zh)
|
2012-05-31 |
2018-09-21 |
索伦托治疗有限公司 |
与pd-l1结合的抗原结合蛋白
|
|
EP2869846A4
(en)
|
2012-07-03 |
2016-01-13 |
Janssen Alzheimer Immunotherap |
C-TERMINAL AND ANTIBODIES WITH CENTRAL A-BETA EPITOP
|
|
JP6461800B2
(ja)
|
2012-10-04 |
2019-01-30 |
デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド |
ヒトモノクローナル抗ｐｄ−ｌ１抗体および使用方法
|
|
WO2014100490A1
(en)
|
2012-12-19 |
2014-06-26 |
Adimab, Llc |
Multivalent antibody analogs, and methods of their preparation and use
|
|
AR093984A1
(es)
|
2012-12-21 |
2015-07-01 |
Merck Sharp & Dohme |
Anticuerpos que se unen a ligando 1 de muerte programada (pd-l1) humano
|
|
GB201311910D0
(en)
|
2013-07-03 |
2013-08-14 |
Glaxosmithkline Ip Dev Ltd |
Novel Compounds
|
|
TWI635098B
(zh)
|
2013-02-01 |
2018-09-11 |
再生元醫藥公司 |
含嵌合恆定區之抗體
|
|
RS57582B1
(sr)
|
2013-02-20 |
2018-11-30 |
Regeneron Pharma |
Nehumane životinje sa modifikovanim sekvencama imunoglobulinskog teškog lanca
|
|
MX364591B
(es)
|
2013-03-15 |
2019-05-02 |
Regeneron Pharma |
Antagonistas de il-33 y usos de estos.
|
|
SMT201700160T1
(it)
|
2013-04-25 |
2017-05-08 |
Beigene Ltd |
Composti eterociclici fusi come inibitori di protein chinasi
|
|
CN111423511B
(zh)
|
2013-05-31 |
2024-02-23 |
索伦托药业有限公司 |
与pd-1结合的抗原结合蛋白
|
|
ES2792183T3
(es)
|
2013-09-13 |
2020-11-10 |
Beigene Switzerland Gmbh |
Anticuerpos anti-PD1 y su uso como productos terapéuticos y de diagnóstico
|
|
JP6508785B2
(ja)
|
2013-10-25 |
2019-05-08 |
ファーマサイクリックス エルエルシー |
ブルトンチロシンキナーゼ阻害剤および免疫療法を使用する処置
|
|
JOP20200094A1
(ar)
|
2014-01-24 |
2017-06-16 |
Dana Farber Cancer Inst Inc |
جزيئات جسم مضاد لـ pd-1 واستخداماتها
|
|
CN106604742B
(zh)
|
2014-07-03 |
2019-01-11 |
百济神州有限公司 |
抗pd-l1抗体及其作为治疗剂及诊断剂的用途
|
|
TW201607930A
(zh)
|
2014-07-18 |
2016-03-01 |
百濟神州有限公司 |
作為ｔ７９０ｍ／ｗｔ－ｅｇｆｒ的選擇性和不可逆的激酶抑制劑的５－氨基－４－氨甲醯基－吡唑化合物及其用途
|
|
SI3179992T1
(sl)
|
2014-08-11 |
2022-09-30 |
Acerta Pharma B.V. |
Terapevtske kombinacije zaviralca BTK, zaviralca PD-1 in/ali zaviralca PD-L1
|
|
US10071164B2
(en)
|
2014-08-11 |
2018-09-11 |
Yale University |
Estrogen-related receptor alpha based protac compounds and associated methods of use
|
|
EP3180343A1
(en)
|
2014-08-14 |
2017-06-21 |
Assia Chemical Industries Ltd. |
Solid state forms of ibrutinib
|
|
TW201625304A
(zh)
|
2014-10-24 |
2016-07-16 |
美國禮來大藥廠 |
泌尿上皮癌之療法
|
|
WO2016087994A1
(en)
|
2014-12-05 |
2016-06-09 |
Acerta Pharma B.V. |
Btk inhibitors to treat solid tumors through modulation of the tumor microenvironment
|
|
US10485797B2
(en)
|
2014-12-18 |
2019-11-26 |
Principia Biopharma Inc. |
Treatment of pemphigus
|
|
WO2016105582A1
(en)
|
2014-12-24 |
2016-06-30 |
Nunn Philip A |
Compositions for ileo-jejunal drug delivery
|
|
US9139653B1
(en)
|
2015-04-30 |
2015-09-22 |
Kymab Limited |
Anti-human OX40L antibodies and methods of treatment
|
|
GB201504314D0
(en)
|
2015-03-13 |
2015-04-29 |
Univ Dundee |
Small molecules
|
|
HK1249058A1
(zh)
|
2015-03-18 |
2018-10-26 |
Arvinas, Inc. |
用於增强靶向蛋白质降解的化合物和方法
|
|
CN104777137B
(zh)
|
2015-03-25 |
2018-06-19 |
深圳市贝沃德克生物技术研究院有限公司 |
生物标志物检测用光谱位置调节装置
|
|
IL294138A
(en)
|
2015-05-29 |
2022-08-01 |
Genentech Inc |
Therapeutic and diagnostic methods for cancer
|
|
WO2016197032A1
(en)
|
2015-06-04 |
2016-12-08 |
Arvinas, Inc. |
Imide-based modulators of proteolysis and associated methods of use
|
|
WO2016197114A1
(en)
|
2015-06-05 |
2016-12-08 |
Arvinas, Inc. |
Tank-binding kinase-1 protacs and associated methods of use
|
|
CA2988430A1
(en)
|
2015-07-10 |
2017-01-19 |
Arvinas, Inc. |
Mdm2-based modulators of proteolysis and associated methods of use
|
|
RU2018105094A
(ru)
|
2015-07-13 |
2019-08-14 |
Арвинас, Инк. |
Модуляторы протеолиза на основе аланина и связанные с ними способы применения
|
|
WO2017024465A1
(en)
|
2015-08-10 |
2017-02-16 |
Innovent Biologics (Suzhou) Co., Ltd. |
Pd-1 antibodies
|
|
US10772962B2
(en)
|
2015-08-19 |
2020-09-15 |
Arvinas Operations, Inc. |
Compounds and methods for the targeted degradation of bromodomain-containing proteins
|
|
WO2017046746A1
(en)
|
2015-09-15 |
2017-03-23 |
Acerta Pharma B.V. |
Therapeutic combinations of a btk inhibitor and a gitr binding molecule, a 4-1bb agonist, or an ox40 agonist
|
|
US20190054090A1
(en)
|
2015-10-01 |
2019-02-21 |
Gilead Sciences, Inc. |
Combination of a btk inhibitor and a checkpoint inhibitor for treating cancers
|
|
CN108366992A
(zh)
|
2015-11-02 |
2018-08-03 |
耶鲁大学 |
蛋白水解靶向嵌合体化合物及其制备和应用方法
|
|
CA3020792A1
(en)
|
2016-04-20 |
2017-10-26 |
Glaxosmithkline Intellectual Property Development Limited |
Conjugates comprising ripk2 inhibitors
|
|
EP3455219A4
(en)
|
2016-05-10 |
2019-12-18 |
C4 Therapeutics, Inc. |
AMINE-RELATED C3-GLUTARIMIDE DEGRONIMERS FOR TARGET PROTEIN REDUCTION
|
|
WO2017197056A1
(en)
|
2016-05-10 |
2017-11-16 |
C4 Therapeutics, Inc. |
Bromodomain targeting degronimers for target protein degradation
|
|
EP3455218A4
(en)
|
2016-05-10 |
2019-12-18 |
C4 Therapeutics, Inc. |
C3 CARBON-BASED GLUTARIMIDE DEGRONIMERS FOR TARGET PROTEIN REDUCTION
|
|
WO2017197036A1
(en)
|
2016-05-10 |
2017-11-16 |
C4 Therapeutics, Inc. |
Spirocyclic degronimers for target protein degradation
|
|
PL3458101T3
(pl)
|
2016-05-20 |
2021-05-31 |
F. Hoffmann-La Roche Ag |
Koniugaty PROTAC-przeciwciało i sposoby ich stosowania
|
|
WO2017214491A1
(en)
|
2016-06-09 |
2017-12-14 |
Blinkbio, Inc. |
Silanol based therapeutic payloads
|
|
GB201610147D0
(en)
|
2016-06-10 |
2016-07-27 |
Glaxosmithkline Ip Dev Ltd |
Novel compounds
|
|
CN109475536B
(zh)
|
2016-07-05 |
2022-05-27 |
百济神州有限公司 |
用于治疗癌症的PD-l拮抗剂和RAF抑制剂的组合
|
|
WO2018033853A2
(en)
|
2016-08-16 |
2018-02-22 |
Beigene, Ltd. |
Crystalline form of (s)-7-(1-acryloylpiperidin-4-yl)-2-(4-phenoxyphenyl)-4,5,6,7-tetra-hydropyrazolo[1,5-a]pyrimidine-3-carboxamide, preparation, and uses thereof
|
|
GB201614134D0
(en)
|
2016-08-18 |
2016-10-05 |
Glaxosmithkline Ip Dev Ltd |
Novel compounds
|
|
PT3500299T
(pt)
|
2016-08-19 |
2024-02-21 |
Beigene Switzerland Gmbh |
Combinação de zanubrutinib com um anticorpo anti-cd20 ou anti-pd-1 para utilização no tratamento do cancro
|
|
WO2018036561A1
(en)
|
2016-08-26 |
2018-03-01 |
Beigene, Ltd. |
Anti-tim-3 antibodies and use thereof
|
|
US10793632B2
(en)
|
2016-08-30 |
2020-10-06 |
Xencor, Inc. |
Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors
|
|
WO2018053354A1
(en)
|
2016-09-15 |
2018-03-22 |
Arvinas, Inc. |
Indole derivatives as estrogen receptor degraders
|
|
EP3519051B1
(en)
|
2016-09-27 |
2021-09-22 |
Beigene, Ltd. |
Treatment of cancers using combination comprising parp inhibitors
|
|
HUE070289T2
(hu)
|
2016-10-11 |
2025-05-28 |
Arvinas Operations Inc |
Vegyületek és módszerek az androgénreceptor célzott lebontására
|
|
CN110214148A
(zh)
|
2016-10-14 |
2019-09-06 |
Xencor股份有限公司 |
含有IL-15/IL-15Rα Fc融合蛋白和PD-1抗体片段的双特异性异源二聚体融合蛋白
|
|
WO2018098275A1
(en)
|
2016-11-22 |
2018-05-31 |
Dana-Farber Cancer Institute, Inc. |
Degradation of bruton's tyrosine kinase (btk) by conjugation of btk inhibitors with e3 ligase ligand and methods of use
|
|
EP3544957B1
(en)
|
2016-11-22 |
2024-05-29 |
Dana-Farber Cancer Institute, Inc. |
Degradation of protein kinases by conjugation of protein kinase inhibitors with e3 ligase ligand and methods of use
|
|
CN110461847B
(zh)
|
2017-01-25 |
2022-06-07 |
百济神州有限公司 |
(S)-7-(1-(丁-2-炔酰基)哌啶-4-基)-2-(4-苯氧基苯基)-4,5,6,7-四氢吡唑并[1,5-a]嘧啶-3-甲酰胺的结晶形式、其制备及用途
|
|
EP3612839A1
(en)
|
2017-04-20 |
2020-02-26 |
ADC Therapeutics SA |
Combination therapy
|
|
TW202515616A
(zh)
|
2017-06-26 |
2025-04-16 |
英屬開曼群島商百濟神州有限公司 |
抗pd-1抗體或其抗原結合片段在製備治療用於患有肝細胞癌(hcc)之藥物的用途
|
|
CN110997677A
(zh)
|
2017-08-12 |
2020-04-10 |
百济神州有限公司 |
具有改进的双重选择性的Btk抑制剂
|
|
WO2019108795A1
(en)
|
2017-11-29 |
2019-06-06 |
Beigene Switzerland Gmbh |
Treatment of indolent or aggressive b-cell lymphomas using a combination comprising btk inhibitors
|
|
CN112351794A
(zh)
|
2018-02-09 |
2021-02-09 |
百济神州有限公司 |
用于尿路上皮癌的免疫治疗方法
|
|
GB201803746D0
(en)
|
2018-03-08 |
2018-04-25 |
Ultrahuman Eight Ltd |
PD1 binding agents
|
|
MX2020009773A
(es)
|
2018-03-21 |
2020-10-08 |
Mei Pharma Inc |
Terapia de combinacion.
|
|
WO2020249001A1
(zh)
|
2019-06-10 |
2020-12-17 |
百济神州瑞士有限责任公司 |
一种含有布鲁顿氏酪氨酸激酶抑制剂的口服固体片剂及其制备方法
|
|
TW202112369A
(zh)
|
2019-06-10 |
2021-04-01 |
英屬開曼群島商百濟神州有限公司 |
口服膠囊劑及其製備方法
|
|
WO2021018018A1
(en)
|
2019-07-26 |
2021-02-04 |
Beigene, Ltd. |
Degradation of bruton's tyrosine kinase (btk) by conjugation of btk inidbitors with e3 ligase ligand and methods of use
|